Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|October 15, 2021

Dr. Tagawa on treatment patterns and survival in mCSPC

Author(s)Urology Times staff

Scott T. Tagawa, MD, discusses the background and results of the study, “Treatment patterns and overall survival in metastatic castration-sensitive prostate cancer from 2006 to 2019,” which was presented during the 2021 ESMO Congress.

Tagawa is a professor of Medicine and Urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian/Weill Cornell Medical Center.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation

ByKate Gessner, MD, PhD

July 20th 2026

Jamie Michael, MD, discusses MRI and genomics in active surveillance

ByJamie Michael, MD

July 16th 2026

Ravi Munver, MD, highlights study of first- and second-generation Aquablation systems

ByRavi Munver, MD

July 14th 2026

The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS

ByAdam B. Weiner, MD,Badrinath R. Konety

July 10th 2026

Sender Herschorn, BSc, MDCM, FRCSC, on vibegron efficacy in older men with OAB and BPH

BySender Herschorn, BSc, MDCM, FRCSC

July 8th 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Testosterone deficiency: FAQs from the AUA guideline

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

The MIBC Referral Gap: Why Half of Patients Miss Perioperative Therapy